金吾财讯 | 糖尿病胰岛素输注设备企业Insulet（PODD）披露2026财年第二季度财报。数据显示，Insulet二季度实现非GAAP调整后每股收益1.66美元，超出市场预期14.3%；调整后EBITDA达1.998亿美元，对应利润率24.9%。营业利润率为16.2%，较去年同期有所回落。期内，营收8.017亿美元，同比大增23.5%，较分析师预期高出1.9%；固定汇率口径下收入同比增长22.7%。自由现金流利润率降至7%，相比去年同期27.4%出现明显下滑。公司给出2026年第三季度营收指引中值8.334亿美元，低于华尔街预期的8.473亿美元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.